Nebivolol Zydus (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebivolol Zydus, is a beta blocker presented as an oral tablet for oral administration. It selectively antagonizes β1‑adrenergic receptors while stimulating nitric oxide release, resulting in vasodilation and reduced systemic vascular resistance, thereby lowering blood pressure in adult patients diagnosed with hypertension.

GNH USA supplies Nebivolol Zydus as a licensed, GDP‑compliant international pharmaceutical product, providing reliable access to hospitals, pharmacies and clinics worldwide, and supporting therapeutic needs across the European Union market through established distribution networks and quality assurance processes.

Nebivolol Zydus is a beta‑blocker that acts on the cardiovascular system to control elevated blood pressure.

- Essential hypertension: lowers systolic and diastolic blood pressure in adult patients. - Secondary hypertension: contributes to blood pressure control when hypertension is due to identifiable causes. - Isolated systolic hypertension: reduces elevated systolic pressure in older adults.

Nebivolol may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate pain in the head region. - Dizziness: sensation of light‑headedness, especially on standing. - Fatigue: unusual tiredness or lack of energy. - Bradycardia: slower than normal heart rate. - Nausea: feeling of stomach upset. - Peripheral edema: swelling of the lower limbs.

Serious or Rare Side Effects: - Severe bradycardia: markedly slow heart rate requiring medical attention. - Hypotension: dangerously low blood pressure. - Atrioventricular block: impaired electrical conduction in the heart. - Bronchospasm: narrowing of airways, especially in asthmatic patients. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Liver enzyme elevation: abnormal liver function tests.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Blood pressure monitoring: check regularly to ensure therapeutic response. - Heart rate assessment: observe for bradycardia, especially in patients with pre‑existing slow heart rates. - Asthma or COPD caution: beta‑blockade may exacerbate bronchospasm. - Concomitant medications: review for drugs that also lower heart rate or blood pressure. - Renal impairment: consider dose adjustment in patients with reduced kidney function. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Nebivolol can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Verapamil or diltiazem: combined use may cause profound bradycardia or AV block. - Other beta‑blockers: additive effects on heart rate and blood pressure. - CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance hypotensive effect, requiring blood pressure monitoring. - Antihypertensive agents (ACE inhibitors, ARBs): may produce additive blood pressure lowering. - Antidiabetic drugs: nebivolol can mask hypoglycemia symptoms; monitor glucose levels.